Diagnosis and Treatment of Pulmonary Arterial Hypertension

Dustin R. Fraidenburg, Jason Yuan, Sean P. Gaine

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Pulmonary hypertension has become an increasingly identified comorbidity to numerous common disease processes and portends a very poor prognosis. Recent advancements in clinical recognition, innovative imaging modalities, and new classification schemes have shed new light on our understanding of this condition and advanced our treatment options. The principal subtype, pulmonary arterial hypertension, is a rare, progressive, and fatal condition manifest by elevated blood pressure in the pulmonary circulation as a result of increased pulmonary vascular resistance (PVR). Elevated pulmonary blood pressure increases the afterload of the right ventricle creating strain, which can progress to right ventricular failure and death. This condition is manifest by clinical symptoms including dyspnea, fatigue, and chest pain along with signs of elevated pulmonary pressures and right heart dysfunction. The clinical evaluation of pulmonary hypertension includes numerous invasive and noninvasive testing including blood work, imaging modalities, and right heart catheterization. Treatment of pulmonary hypertension includes both supportive care therapeutics and targeted pulmonary vasodilators. While supportive care with diuretics, oxygen, anticoagulation, and inotropic agents remain commonplace, newer agents including prostacyclin analogs, endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, and guanylate cyclase stimulators have clearly shown safety and efficacy in numerous clinical trials. Recent years have produced substantial progress in our management of pulmonary hypertension; still much needs to be done in order to identify novel targets that may have far-reaching impact on overall morbidity and mortality.

Original languageEnglish (US)
Title of host publicationPanVascular Medicine, Second Edition
PublisherSpringer Berlin Heidelberg
Pages4105-4133
Number of pages29
ISBN (Print)9783642370786, 9783642370779
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Blood pressure
Pulmonary Hypertension
Imaging techniques
Phosphodiesterase 5 Inhibitors
Guanylate Cyclase
Epoprostenol
Vasodilator Agents
Diuretics
Blood
Lung
Fatigue of materials
Oxygen
Blood Pressure
Testing
Therapeutics
Pulmonary Circulation
Cardiac Catheterization
Chest Pain
Vascular Resistance
Dyspnea

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Fraidenburg, D. R., Yuan, J., & Gaine, S. P. (2015). Diagnosis and Treatment of Pulmonary Arterial Hypertension. In PanVascular Medicine, Second Edition (pp. 4105-4133). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-642-37078-6_159

Diagnosis and Treatment of Pulmonary Arterial Hypertension. / Fraidenburg, Dustin R.; Yuan, Jason; Gaine, Sean P.

PanVascular Medicine, Second Edition. Springer Berlin Heidelberg, 2015. p. 4105-4133.

Research output: Chapter in Book/Report/Conference proceedingChapter

Fraidenburg, DR, Yuan, J & Gaine, SP 2015, Diagnosis and Treatment of Pulmonary Arterial Hypertension. in PanVascular Medicine, Second Edition. Springer Berlin Heidelberg, pp. 4105-4133. https://doi.org/10.1007/978-3-642-37078-6_159
Fraidenburg DR, Yuan J, Gaine SP. Diagnosis and Treatment of Pulmonary Arterial Hypertension. In PanVascular Medicine, Second Edition. Springer Berlin Heidelberg. 2015. p. 4105-4133 https://doi.org/10.1007/978-3-642-37078-6_159
Fraidenburg, Dustin R. ; Yuan, Jason ; Gaine, Sean P. / Diagnosis and Treatment of Pulmonary Arterial Hypertension. PanVascular Medicine, Second Edition. Springer Berlin Heidelberg, 2015. pp. 4105-4133
@inbook{4b6224f439df4e11873ef468c5ffc6ea,
title = "Diagnosis and Treatment of Pulmonary Arterial Hypertension",
abstract = "Pulmonary hypertension has become an increasingly identified comorbidity to numerous common disease processes and portends a very poor prognosis. Recent advancements in clinical recognition, innovative imaging modalities, and new classification schemes have shed new light on our understanding of this condition and advanced our treatment options. The principal subtype, pulmonary arterial hypertension, is a rare, progressive, and fatal condition manifest by elevated blood pressure in the pulmonary circulation as a result of increased pulmonary vascular resistance (PVR). Elevated pulmonary blood pressure increases the afterload of the right ventricle creating strain, which can progress to right ventricular failure and death. This condition is manifest by clinical symptoms including dyspnea, fatigue, and chest pain along with signs of elevated pulmonary pressures and right heart dysfunction. The clinical evaluation of pulmonary hypertension includes numerous invasive and noninvasive testing including blood work, imaging modalities, and right heart catheterization. Treatment of pulmonary hypertension includes both supportive care therapeutics and targeted pulmonary vasodilators. While supportive care with diuretics, oxygen, anticoagulation, and inotropic agents remain commonplace, newer agents including prostacyclin analogs, endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, and guanylate cyclase stimulators have clearly shown safety and efficacy in numerous clinical trials. Recent years have produced substantial progress in our management of pulmonary hypertension; still much needs to be done in order to identify novel targets that may have far-reaching impact on overall morbidity and mortality.",
author = "Fraidenburg, {Dustin R.} and Jason Yuan and Gaine, {Sean P.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-3-642-37078-6_159",
language = "English (US)",
isbn = "9783642370786",
pages = "4105--4133",
booktitle = "PanVascular Medicine, Second Edition",
publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Diagnosis and Treatment of Pulmonary Arterial Hypertension

AU - Fraidenburg, Dustin R.

AU - Yuan, Jason

AU - Gaine, Sean P.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Pulmonary hypertension has become an increasingly identified comorbidity to numerous common disease processes and portends a very poor prognosis. Recent advancements in clinical recognition, innovative imaging modalities, and new classification schemes have shed new light on our understanding of this condition and advanced our treatment options. The principal subtype, pulmonary arterial hypertension, is a rare, progressive, and fatal condition manifest by elevated blood pressure in the pulmonary circulation as a result of increased pulmonary vascular resistance (PVR). Elevated pulmonary blood pressure increases the afterload of the right ventricle creating strain, which can progress to right ventricular failure and death. This condition is manifest by clinical symptoms including dyspnea, fatigue, and chest pain along with signs of elevated pulmonary pressures and right heart dysfunction. The clinical evaluation of pulmonary hypertension includes numerous invasive and noninvasive testing including blood work, imaging modalities, and right heart catheterization. Treatment of pulmonary hypertension includes both supportive care therapeutics and targeted pulmonary vasodilators. While supportive care with diuretics, oxygen, anticoagulation, and inotropic agents remain commonplace, newer agents including prostacyclin analogs, endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, and guanylate cyclase stimulators have clearly shown safety and efficacy in numerous clinical trials. Recent years have produced substantial progress in our management of pulmonary hypertension; still much needs to be done in order to identify novel targets that may have far-reaching impact on overall morbidity and mortality.

AB - Pulmonary hypertension has become an increasingly identified comorbidity to numerous common disease processes and portends a very poor prognosis. Recent advancements in clinical recognition, innovative imaging modalities, and new classification schemes have shed new light on our understanding of this condition and advanced our treatment options. The principal subtype, pulmonary arterial hypertension, is a rare, progressive, and fatal condition manifest by elevated blood pressure in the pulmonary circulation as a result of increased pulmonary vascular resistance (PVR). Elevated pulmonary blood pressure increases the afterload of the right ventricle creating strain, which can progress to right ventricular failure and death. This condition is manifest by clinical symptoms including dyspnea, fatigue, and chest pain along with signs of elevated pulmonary pressures and right heart dysfunction. The clinical evaluation of pulmonary hypertension includes numerous invasive and noninvasive testing including blood work, imaging modalities, and right heart catheterization. Treatment of pulmonary hypertension includes both supportive care therapeutics and targeted pulmonary vasodilators. While supportive care with diuretics, oxygen, anticoagulation, and inotropic agents remain commonplace, newer agents including prostacyclin analogs, endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, and guanylate cyclase stimulators have clearly shown safety and efficacy in numerous clinical trials. Recent years have produced substantial progress in our management of pulmonary hypertension; still much needs to be done in order to identify novel targets that may have far-reaching impact on overall morbidity and mortality.

UR - http://www.scopus.com/inward/record.url?scp=84956969167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956969167&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-37078-6_159

DO - 10.1007/978-3-642-37078-6_159

M3 - Chapter

SN - 9783642370786

SN - 9783642370779

SP - 4105

EP - 4133

BT - PanVascular Medicine, Second Edition

PB - Springer Berlin Heidelberg

ER -